Prime Medicine (NASDAQ:PRME) Shares Cross Below 50 Day Moving Average - What's Next?

Prime Medicine logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Prime Medicine shares fell below their 50-day moving average of $3.74, trading as low as $3.49 and last at $3.55.
  • Analysts’ consensus rating is “Moderate Buy”, with an average price target of $7.86; targets cited range from $7 to $9.
  • For the latest quarter, Prime Medicine reported a loss of $0.22 per share, slightly better than analysts’ $0.23 loss estimate, and revenue of $4.21 million.
  • Five stocks to consider instead of Prime Medicine.

Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $3.74 and traded as low as $3.49. Prime Medicine shares last traded at $3.55, with a volume of 6,127,062 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PRME. Chardan Capital reiterated a "buy" rating and issued a $7.00 price target on shares of Prime Medicine in a report on Friday, September 25th. BMO Capital Markets began coverage on shares of Prime Medicine in a research note on Tuesday, August 18th. They issued an "outperform" rating and a $9.00 target price on the stock. Wall Street Zen raised Prime Medicine from a "sell" rating to a "hold" rating in a research note on Saturday, October 31st. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of Prime Medicine in a research report on Monday, November 16th. Finally, Citigroup reissued a "market outperform" rating on shares of Prime Medicine in a research report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $7.86.

View Our Latest Research Report on Prime Medicine

Prime Medicine Stock Down 7.6%

The company has a market capitalization of $645.82 million, a PE ratio of -3.70 and a beta of 2.14. The business has a 50 day simple moving average of $3.74 and a 200 day simple moving average of $3.51.

Prime Medicine (NASDAQ:PRME - Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 222.88%. The business had revenue of $4.21 million for the quarter. Equities analysts expect that Prime Medicine, Inc. will post -0.94 EPS for the current fiscal year.

Institutional Trading of Prime Medicine

Several large investors have recently made changes to their positions in the business. Royal Bank of Canada grew its position in Prime Medicine by 89.3% during the 1st quarter. Royal Bank of Canada now owns 9,254 shares of the company's stock worth $32,000 after purchasing an additional 4,365 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Prime Medicine in the 3rd quarter valued at $28,000. Kingsview Wealth Management LLC acquired a new stake in shares of Prime Medicine in the second quarter valued at about $37,000. Wealthfront Advisers LLC acquired a new stake in Prime Medicine in the 1st quarter worth about $36,000. Finally, Syon Capital LLC purchased a new stake in shares of Prime Medicine during the second quarter worth approximately $41,000. 70.37% of the stock is owned by hedge funds and other institutional investors.

Prime Medicine Company Profile

(Get Free Report)

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Prime Medicine Right Now?

Before you consider Prime Medicine, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.

While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines